Ultragenyx Pharmaceutical Inc. RARE
We take great care to ensure that the data presented and summarized in this overview for Ultragenyx Pharmaceutical Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RARE
View all-
Vanguard Group Inc Valley Forge, PA10MShares$414 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$232 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$173 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$133 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$109 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA2.45MShares$102 Million0.02% of portfolio
-
Clearbridge Investments, LLC New York, NY2.26MShares$93.6 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.15MShares$89.1 Million0.15% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA2.06MShares$85.2 Million0.17% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.02MShares$83.9 Million3.21% of portfolio
Latest Institutional Activity in RARE
Top Purchases
Top Sells
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Insider Transactions at RARE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 20
2025
|
Corazon (Corsee) D. Sanders |
SELL
Open market or private sale
|
Direct |
2,405
-13.55%
|
$88,985
$37.39 P/Share
|
May 15
2025
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+19.72%
|
-
|
May 15
2025
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+15.7%
|
-
|
May 15
2025
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+18.12%
|
-
|
May 15
2025
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+14.94%
|
-
|
May 15
2025
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+24.44%
|
-
|
May 15
2025
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+14.94%
|
-
|
May 15
2025
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+18.12%
|
-
|
May 05
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
520
-0.72%
|
$20,280
$39.24 P/Share
|
Apr 21
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
242
-0.34%
|
$8,470
$35.11 P/Share
|
Mar 06
2025
|
Howard Horn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,785
-1.65%
|
$71,400
$40.4 P/Share
|
Mar 03
2025
|
Thomas Richard Kassberg CBO & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
508
-0.19%
|
$21,336
$42.92 P/Share
|
Mar 03
2025
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
6,028
-2.22%
|
$253,176
$42.1 P/Share
|
Mar 03
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,945
-11.06%
|
$375,690
$42.1 P/Share
|
Mar 03
2025
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,846
-14.58%
|
$539,532
$42.1 P/Share
|
Mar 03
2025
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
73,434
-10.27%
|
$3,084,228
$42.1 P/Share
|
Mar 03
2025
|
John Richard Pinion |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.03%
|
$1,302
$42.92 P/Share
|
Mar 03
2025
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
14,439
-11.82%
|
$606,438
$42.1 P/Share
|
Mar 03
2025
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,103
-14.67%
|
$634,326
$42.1 P/Share
|
Mar 03
2025
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-0.28%
|
$5,922
$42.92 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 401K shares |
---|
Payment of exercise price or tax liability | 2.03K shares |
---|---|
Bona fide gift | 20.6K shares |
Open market or private sale | 232K shares |